General MedicationsTOPICALGeneric
METVIXIA
METHYL AMINOLEVULINATE HYDROCHLORIDE
Standard Dose
EQ 16.8% BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview METVIXIA is listed in Drugs@FDA under application 021415 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient METHYL AMINOLEVULINATE HYDROCHLORIDE Form and strength CREAM;TOPICAL - EQ 16.8% BASE Sponsor GALDERMA LABS LP Submission history Latest submission status date: 2012-11-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview METVIXIA is listed in Drugs@FDA under application 021415 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient METHYL AMINOLEVULINATE HYDROCHLORIDE Form and strength CREAM;TOPICAL - EQ 16.8% BASE Sponsor GALDERMA LABS LP Submission history Latest submission status date: 2012-11-20 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.